Eden Research PLC - Oxfordshire-based sustainable crop protection and animal health firm - Wins approval to use its biofungicide Mevalone and its nematode-formulation Cedroz in the US. Also wins approval to use Mevalone in Italy to control Botrytis cinerea, which is a fungal pathogen. Mevalone is also authorised for use against fungal pathogens Powdery Mildew and Sclerotinia.

Mevalone is sold exclusively in Italy by Eden’s commercial partner, Sipcam Oxon SpA, under the brand name ‘3logy,’ Eden adds. The addressable markets in the US are about €94 million for Mevalone and €189 million for Cedroz, the firm says. ‘With the demand for biopesticides such as these increasing significantly in the US due to rising regulatory restrictions for conventional chemicals, the tolerance exemption and subsequent approvals will present a significant opportunity for Eden,’ the company adds.

Current stock price: 5.01 pence, up 5.5% on Tuesday

12-month change: down 67%

Copyright 2022 Alliance News Limited. All Rights Reserved.